Clinical Trials Arena

Clinicaltrialsarena.com is part of a unique network of over 40 specialized B2B websites, reaching a vast global audience of key decision-makers, influencers, and thought leaders, totaling 55 million industry professionals annually. As a division of GlobalData, we leverage an extensive database of more than 1 billion data points related to companies, deals, projects, forecasts, and market trends. Our top-tier content is backed by this comprehensive data. With expertise across more than 80 global markets and a dedicated team of over 800 award-winning journalists, researchers, and analysts, we provide you with crucial insights that can significantly impact business success every day.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#238523

United States

#163170

Health/Biotechnology and Pharmaceuticals

#123

Traffic sources

Monthly visitors

Articles

Developing resilient strategies to overcome challenges in clinical research in Europe

1 week ago | clinicaltrialsarena.com | Robert Barrie

At the 15th Annual Outsourcing in Clinical Trials (OCT) Europe conference, which took place between 29 and 30 April in Barcelona, Spain, industry experts delivered comprehensive insights, examined emerging trends and tackled regulatory and operational challenges of clinical trials nowadays.
FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use

1 week ago | clinicaltrialsarena.com | Manasi Vaidya

US Food and Drug Administration (FDA) Commissioner Dr. Marty Makary addressed concerns about the recent cuts impacting the agency’s ability to function by emphasising that they did not affect scientific reviewers or inspectors, at an ongoing industry meeting. “I’m proud to report that we’re on track to meet all the newfound targets, and that morale is good and improving at the agency,” said Makary.
Ensuring success in oncology clinical trials

1 week ago | clinicaltrialsarena.com | Ross Law

Oncology clinical trials are complex and costly, making successful setup critical. Challenges include long timelines and patient recruitment. Patient-centric approaches such as AI, digital twins, and decentralised trials are improving enrolment, especially for cancer patients but 2025 has given rise to new headwinds.
Tough funding environment is impacting trial activity in the US

1 week ago | clinicaltrialsarena.com | Irena Maragkou

An analysis of clinical trial registries, including ClinicalTrials.gov and Australian and New Zealand registries, has shown a 20% reduction in overall trial activity compared to this time last year, with oncology trials being hit hardest, said Aditya Kotta, Head of Business Development of US and EU at global contract research organisation (CRO) Novotech.
Novo Nordisk ramps up obesity fight, advances amycretin to Phase III

2 weeks ago | clinicaltrialsarena.com | Abigail Beaney

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo Nordisk shared that regulatory authorities have approved the therapy to proceed. The company plans to initiate the trial in adults who are overweight or with obesity in Q1 2026.
AI could personalise clinical trial consent, but privacy concerns remain

2 weeks ago | clinicaltrialsarena.com | Frankie Fattorini

Artificial intelligence (AI) is revolutionising clinical trials, offering ways to improve the consent process, but concerns regarding the complete reliability of the technology for sensitive tasks persist. The limitations of AI to enhance trial participant engagement, and how it may overcome these, were outlined by Blanka Hezelova, associate director at GSK on 11 June.
Clinician capacity remains a major bottleneck in UK’s push for cancer trials

2 weeks ago | clinicaltrialsarena.com | Frankie Fattorini

While encouraged by revised regulations aimed at boosting UK clinical studies, experts say busy schedules of NHS workers present a major bottleneck to the country’s ability to conduct cancer trials. An expert panel said the nation’s doctors and nurses have limited time or incentive to better support clinical trials through the National Health Service (NHS).
Policy changes and digital strategies guide oncology research

2 weeks ago | clinicaltrialsarena.com | Irena Maragkou

Against the backdrop of the recent US Food and Drug Administration’s (FDA) staff cuts and administrative realignment, understanding accelerated approval regulatory pathways, implementing pragmatic approaches and digital solutions is becoming more significant in the oncology clinical trial space.
American Society of Clinical Oncology (ASCO) Annual Meeting 2025

2 weeks ago | clinicaltrialsarena.com | Nikki Thompson

The American Society of Clinical Oncology (ASCO) Annual Meeting 2025, held from 30 May to 3 June, in Chicago, Illinois, showcased a sweeping array of oncological advancements, with 5,483 total presentations. This leading global forum delivered critical updates on emerging therapies, pivotal clinical trial outcomes, and evolving standards of care across a wide spectrum of cancer types. AstraZeneca dominated the event in terms of share of voice, followed by Pfizer and Cellular Therapeutics.
AI should unlock clinical trial data, say experts

2 weeks ago | clinicaltrialsarena.com | Catherine Longworth

Artificial intelligence (AI) has the potential to uncover valuable insights hidden in protocols and clinical study reports across the pharmaceutical industry, according to experts at the Outsourcing in Clinical Trials East Coast 2025 conference in King of Prussia.